Altamirano-Espinoza A H, González-Hernández A, Manrique-Maldonado G, Marichal-Cancino B A, Ruiz-Salinas I, Villalón C M
Departamento de Farmacobiología, Cinvestav-Coapa, México D.F., México.
Br J Pharmacol. 2013 Nov;170(5):1102-11. doi: 10.1111/bph.12358.
Quinpirole (a dopamine D2-like receptor agonist) inhibits the cardioaccelerator sympathetic outflow in pithed rats by sympathoinhibitory D2-like receptors. The present study was designed to identify pharmacologically the specific D2-like receptor subtypes (i.e. D2 , D3 and D4) involved in this sympathoinhibition by quinpirole.
One hundred fourteen male Wistar rats were pithed, artificially ventilated with room air and prepared for either preganglionic spinal (C7-T1) stimulation of the cardioaccelerator sympathetic outflow (n = 102) or i.v. bolus injections of exogenous noradrenaline (n = 12). This approach resulted in frequency-dependent and dose-dependent tachycardic responses, respectively, as previously reported by our group.
I.v. continuous infusions of quinpirole (0.1-10 μg kg(-1) min(-1)), but not of saline (0.02 mL min(-1)), dose-dependently inhibited the sympathetically induced tachycardic responses. Moreover, the cardiac sympathoinhibition induced by 3 μg kg(-1) min(-1) quinpirole (which failed to affect the tachycardic responses to i.v. noradrenaline) was: (i) unchanged after i.v. injections of the antagonists SB-277011-A (D3 ; 100-300 μg kg(-1)) or L-745,870 (D4 ; 30-100 μg kg(-1)); and (ii) markedly blocked and abolished by, respectively, 100 and 300 μg kg(-1) of the D2 preferring receptor subtype antagonist L-741,626. These doses of antagonists, which did not affect per se the sympathetically induced tachycardic responses, were high enough to completely block their respective receptors.
The cardiac sympathoinhibition induced by 3 μg kg(-1) min(-1) quinpirole involves the dopamine D2 receptor subtype, with no evidence for the involvement of the D3 or D4 subtypes. This provides new evidence for understanding the modulation of the cardioaccelerator sympathetic outflow.
喹吡罗(一种多巴胺D2样受体激动剂)通过交感抑制性D2样受体抑制脊髓横断大鼠的心脏加速交感神经传出。本研究旨在从药理学角度确定参与喹吡罗所致这种交感抑制作用的特定D2样受体亚型(即D2、D3和D4)。
114只雄性Wistar大鼠被脊髓横断,用室内空气进行人工通气,并准备用于节前脊髓(C7-T1)刺激心脏加速交感神经传出(n = 102)或静脉推注外源性去甲肾上腺素(n = 12)。如我们小组之前所报道,这种方法分别导致频率依赖性和剂量依赖性心动过速反应。
静脉持续输注喹吡罗(0.1 - 10 μg kg⁻¹ min⁻¹),而非生理盐水(0.02 mL min⁻¹),剂量依赖性地抑制交感神经诱导的心动过速反应。此外,3 μg kg⁻¹ min⁻¹喹吡罗诱导的心脏交感抑制作用(该剂量未能影响静脉注射去甲肾上腺素引起的心动过速反应):(i)静脉注射拮抗剂SB - 277011 - A(D3;100 - 300 μg kg⁻¹)或L - 745,870(D4;30 - 100 μg kg⁻¹)后无变化;(ii)分别被100和300 μg kg⁻¹的D2选择性受体亚型拮抗剂L - 741,626显著阻断和消除。这些拮抗剂剂量本身不影响交感神经诱导的心动过速反应,但足以完全阻断其各自的受体。
3 μg kg⁻¹ min⁻¹喹吡罗诱导的心脏交感抑制作用涉及多巴胺D2受体亚型,没有证据表明D3或D4亚型参与其中。这为理解心脏加速交感神经传出的调节提供了新证据。